NCT04463472View on ClinicalTrials.gov

Study of COVID-19 DNA Vaccine (AG0301-COVID19)

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

June 29, 2020

Primary Completion Date

September 28, 2020

Study Completion Date

August 12, 2021

Conditions
COVID-19
Interventions
BIOLOGICAL

AG0301-COVID19

1.0 mg of AG0301-COVID19 twice at 2-week intervals

BIOLOGICAL

AG0301-COVID19

2.0 mg of AG0301-COVID19 twice at 2-week intervals

Trial Locations (1)

Unknown

Osaka City University Hospital, Osaka

Sponsors
All Listed Sponsors
collaborator

Japan Agency for Medical Research and Development

OTHER_GOV

lead

AnGes, Inc.

INDUSTRY